Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Front-line use of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: Practice considerations.

Reff MJ, Shillingburg A, Shah B, Elder C, Prescott H, Kennerly-Shah J.

J Oncol Pharm Pract. 2019 Jul 27:1078155219864640. doi: 10.1177/1078155219864640. [Epub ahead of print]

PMID:
31354102
2.

Collaboration Leads to Oral Chemotherapy Education.

Glode AE, Holle L, Nubla J, Minjock M, Egerton N, LeFebvre K, Reff M, DeRemer D.

J Adv Pract Oncol. 2018 Nov-Dec;9(7):755-756. Epub 2018 Nov 1. Review.

3.

Positive quality interventions: an innovative platform for oncology practice collaboration.

Nubla J, Dave N, Reff M.

Am J Manag Care. 2017 Oct;23(12 Spec No.):SP500-SP501. No abstract available.

4.

Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).

Zhang L, Fan J, Chong JH, Cesena A, Tam BY, Gilson C, Boykin C, Wang D, Aivazian D, Marcotte D, Xiao G, Le Brazidec JY, Piao J, Lundgren K, Hong K, Vu K, Nguyen K, Gan LS, Silvian L, Ling L, Teng M, Reff M, Takeda N, Timple N, Wang Q, Morena R, Khan S, Zhao S, Li T, Lee WC, Taveras AG, Chao J.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5633-7. doi: 10.1016/j.bmcl.2011.06.129. Epub 2011 Jul 13.

PMID:
21798738
5.

A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.

Dong J, Sereno A, Aivazian D, Langley E, Miller BR, Snyder WB, Chan E, Cantele M, Morena R, Joseph IB, Boccia A, Virata C, Gamez J, Yco G, Favis M, Wu X, Graff CP, Wang Q, Rohde E, Rennard R, Berquist L, Huang F, Zhang Y, Gao SX, Ho SN, Demarest SJ, Reff ME, Hariharan K, Glaser SM.

MAbs. 2011 May-Jun;3(3):273-88. Epub 2011 May 1.

6.

Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity.

Dong J, Sereno A, Snyder WB, Miller BR, Tamraz S, Doern A, Favis M, Wu X, Tran H, Langley E, Joseph I, Boccia A, Kelly R, Wortham K, Wang Q, Berquist L, Huang F, Gao SX, Zhang Y, Lugovskoy A, Martin S, Gouvis H, Berkowitz S, Chiang G, Reff M, Glaser SM, Hariharan K, Demarest SJ.

J Biol Chem. 2011 Feb 11;286(6):4703-17. doi: 10.1074/jbc.M110.184317. Epub 2010 Dec 1.

7.

Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response.

Dong J, Demarest SJ, Sereno A, Tamraz S, Langley E, Doern A, Snipas T, Perron K, Joseph I, Glaser SM, Ho SN, Reff ME, Hariharan K.

Mol Cancer Ther. 2010 Sep;9(9):2593-604. doi: 10.1158/1535-7163.MCT-09-1018. Epub 2010 Aug 17.

8.

Characterization of inhibitory anti-insulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: implications for mechanism of action in vivo.

Doern A, Cao X, Sereno A, Reyes CL, Altshuler A, Huang F, Hession C, Flavier A, Favis M, Tran H, Ailor E, Levesque M, Murphy T, Berquist L, Tamraz S, Snipas T, Garber E, Shestowsky WS, Rennard R, Graff CP, Wu X, Snyder W, Cole L, Gregson D, Shields M, Ho SN, Reff ME, Glaser SM, Dong J, Demarest SJ, Hariharan K.

J Biol Chem. 2009 Apr 10;284(15):10254-67. doi: 10.1074/jbc.M809709200. Epub 2009 Feb 11.

9.

Conserved amino acid networks involved in antibody variable domain interactions.

Wang N, Smith WF, Miller BR, Aivazian D, Lugovskoy AA, Reff ME, Glaser SM, Croner LJ, Demarest SJ.

Proteins. 2009 Jul;76(1):99-114. doi: 10.1002/prot.22319.

PMID:
19089973
10.

Enhanced cell culture performance using inducible anti-apoptotic genes E1B-19K and Aven in the production of a monoclonal antibody with Chinese hamster ovary cells.

Figueroa B Jr, Ailor E, Osborne D, Hardwick JM, Reff M, Betenbaugh MJ.

Biotechnol Bioeng. 2007 Jul 1;97(4):877-92.

PMID:
17099908
11.

Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy.

Lukashev M, LePage D, Wilson C, Bailly V, Garber E, Lukashin A, Ngam-ek A, Zeng W, Allaire N, Perrin S, Xu X, Szeliga K, Wortham K, Kelly R, Bottiglio C, Ding J, Griffith L, Heaney G, Silverio E, Yang W, Jarpe M, Fawell S, Reff M, Carmillo A, Miatkowski K, Amatucci J, Crowell T, Prentice H, Meier W, Violette SM, Mackay F, Yang D, Hoffman R, Browning JL.

Cancer Res. 2006 Oct 1;66(19):9617-24.

12.

Novel antibody hinge regions for efficient production of CH2 domain-deleted antibodies.

Glaser SM, Hughes IE, Hopp JR, Hathaway K, Perret D, Reff ME.

J Biol Chem. 2005 Dec 16;280(50):41494-503. Epub 2005 Oct 12.

13.

Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects.

Poole JA, Meng J, Reff M, Spellman MC, Rosenwasser LJ.

J Allergy Clin Immunol. 2005 Oct;116(4):780-8.

PMID:
16210051
14.

Future of monoclonal antibodies in the treatment of hematologic malignancies.

Reff ME, Hariharan K, Braslawsky G.

Cancer Control. 2002 Mar-Apr;9(2):152-66. Review.

PMID:
11965235
15.

Anti-CD23 monoclonal antibody inhibits germline Cepsilon transcription in B cells.

Yabuuchi S, Nakamura T, Kloetzer WS, Reff ME.

Int Immunopharmacol. 2002 Mar;2(4):453-61.

PMID:
11962725
16.

Future approaches for treating hematologic disease.

Reff M, Braslawsky G, Hanna N.

Curr Pharm Biotechnol. 2001 Dec;2(4):369-82. Review.

PMID:
11762418
17.

A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications.

Reff ME, Heard C.

Crit Rev Oncol Hematol. 2001 Oct;40(1):25-35. Review.

PMID:
11578914
18.

Efficacy of the anti-angiogenic approach to solid tumors.

Reff M.

Drug Discov Today. 2001 Jul 1;6(14):716-717. No abstract available.

PMID:
11445462
19.
21.

Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees.

Newman R, Hariharan K, Reff M, Anderson DR, Braslawsky G, Santoro D, Hanna N, Bugelski PJ, Brigham-Burke M, Crysler C, Gagnon RC, Dal Monte P, Doyle ML, Hensley PC, Reddy MP, Sweet RW, Truneh A.

Clin Immunol. 2001 Feb;98(2):164-74.

PMID:
11161972
22.

Measurement of protein interaction bioenergetics: application to structural variants of anti-sCD4 antibody.

Doyle ML, Brigham-Burke M, Blackburn MN, Brooks IS, Smith TM, Newman R, Reff M, Stafford WF 3rd, Sweet RW, Truneh A, Hensley P, O'Shannessy DJ.

Methods Enzymol. 2000;323:207-30.

PMID:
10944754
23.

In vitro IgE inhibition in B cells by anti-CD23 monoclonal antibodies is functionally dependent on the immunoglobulin Fc domain.

Nakamura T, Kloetzer WS, Brams P, Hariharan K, Chamat S, Cao X, LaBarre MJ, Chinn PC, Morena RA, Shestowsky WS, Li YP, Chen A, Reff ME.

Int J Immunopharmacol. 2000 Feb;22(2):131-41.

PMID:
10684997
24.

Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4.

Reddy MP, Kinney CA, Chaikin MA, Payne A, Fishman-Lobell J, Tsui P, Dal Monte PR, Doyle ML, Brigham-Burke MR, Anderson D, Reff M, Newman R, Hanna N, Sweet RW, Truneh A.

J Immunol. 2000 Feb 15;164(4):1925-33.

25.

Integrin-dependent tyrosine phosphorylation and growth regulation by Vav.

Yron I, Deckert M, Reff ME, Munshi A, Schwartz MA, Altman A.

Cell Adhes Commun. 1999;7(1):1-11.

PMID:
10228731
26.

Two neutralizing human anti-RSV antibodies: cloning, expression, and characterization.

Heard C, Brams P, Walsh E, Huynh T, Chamat S, Reff M, Owyang A, Shestowsky W, Newman R.

Mol Med. 1999 Jan;5(1):35-45.

28.

A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4.

Anderson D, Chambers K, Hanna N, Leonard J, Reff M, Newman R, Baldoni J, Dunleavy D, Reddy M, Sweet R, Truneh A.

Clin Immunol Immunopathol. 1997 Jul;84(1):73-84.

PMID:
9191886
29.

Simple differentiation between core-fucosylated and nonfucosylated glycans by capillary electrophoresis.

Okafo GN, Burrow LM, Neville W, Truneh A, Smith RA, Reff M, Camilleri P.

Anal Biochem. 1996 Aug 15;240(1):68-74.

PMID:
8811881
30.

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR.

Blood. 1994 Jan 15;83(2):435-45.

PMID:
7506951
31.

High-level production of recombinant immunoglobulins in mammalian cells.

Reff ME.

Curr Opin Biotechnol. 1993 Oct;4(5):573-6.

PMID:
7764208
32.

"Primatization" of recombinant antibodies for immunotherapy of human diseases: a macaque/human chimeric antibody against human CD4.

Newman R, Alberts J, Anderson D, Carner K, Heard C, Norton F, Raab R, Reff M, Shuey S, Hanna N.

Biotechnology (N Y). 1992 Nov;10(11):1455-60.

PMID:
1369023
33.

Quantitative immunocytochemical staining for recombinant tissue-type plasminogen activator in transfected Chinese hamster ovary cells.

Gennaro DE, Hoffstein ST, Marks G, Ramos L, Oka MS, Reff ME, Hart TK, Bugelski PJ.

Proc Soc Exp Biol Med. 1991 Oct;198(1):591-8.

PMID:
1909792
34.
35.
37.

DHFR coamplification of t-PA in DHFR+ bovine endothelial cells: in vitro characterization of the purified serine protease.

Connors RW, Sweet RW, Noveral JP, Pfarr DS, Trill JJ, Shebuski RJ, Berkowitz BA, Williams D, Franklin S, Reff ME.

DNA. 1988 Nov;7(9):651-61.

PMID:
3147883
38.
39.

Differential effects of polyadenylation regions on gene expression in mammalian cells.

Pfarr DS, Rieser LA, Woychik RP, Rottman FM, Rosenberg M, Reff ME.

DNA. 1986 Apr;5(2):115-22.

PMID:
2872023
40.
41.

Analysis of regenerating hepatic cell replication in vivo by differential chromatid staining.

Kato H, Reff M, Schneider EL.

Cell Tissue Kinet. 1982 Nov;15(6):637-42.

PMID:
6184167
42.

Cell culture aging.

Reff M, Schneider EL.

Mol Cell Biochem. 1981 May 26;36(3):169-76. Review.

PMID:
7019665
43.
44.
45.

Conformation differences in bacterial ribosomal RNA's in non-denaturing conditions.

Reff ME, Stanbridge EJ.

Nature. 1976 Apr 22;260(5553):724-6. No abstract available.

PMID:
817211

Supplemental Content

Support Center